In the latest trading session,, 0.42 million Astria Therapeutics Inc (NASDAQ:ATXS) shares changed hands as the company’s beta touched 0.66. With the company’s most recent per share price at $3.75 changing hands around $0.0 or 0.00% at last look, the market valuation stands at $211.63M. ATXS’s current price is a discount, trading about -244.53% off its 52-week high of $12.92. The share price had its 52-week low at $3.70, which suggests the last value was 1.33% up since then. When we look at Astria Therapeutics Inc’s average trading volume, we note the 10-day average is 0.31 million shares, with the 3-month average coming to 284.74K.
Analysts gave the Astria Therapeutics Inc (ATXS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATXS as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Astria Therapeutics Inc’s EPS for the current quarter is expected to be -0.48.
Astria Therapeutics Inc (NASDAQ:ATXS) trade information
The company’s shares are showing year-to-date downside of -58.05%, with the 5-day performance at -32.07% in the red. However, in the 30-day time frame, Astria Therapeutics Inc (NASDAQ:ATXS) is -42.04% down. Looking at the short shares, we see there were 3.19 million shares sold at short interest cover period of 13.12 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22.5, meaning bulls need an upside of 83.33% from its recent market value. According to analyst projections, ATXS’s forecast low is 20 with 25 as the target high. To hit the forecast high, the stock’s price needs a -566.67% plunge from its current level, while the stock would need to soar -433.33% for it to hit the projected low.
Astria Therapeutics Inc (ATXS) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.65%. The 2025 estimates are for Astria Therapeutics Inc earnings to decrease by -16.58%, but the outlook for the next 5-year period is at -8.54% per year.
Astria Therapeutics Inc (NASDAQ:ATXS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.47% of Astria Therapeutics Inc shares while 104.65% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 105.15%. There are 104.65% institutions holding the Astria Therapeutics Inc stock share, with PERCEPTIVE ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 11.4815% of the shares, roughly 6.49 million ATXS shares worth $59.02 million.
FMR LLC holds the second largest percentage of outstanding shares, with 10.7187% or 6.05 million shares worth $55.1 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Securities Fund-Fidelity Small Cap Growth Fund . With 1.56 shares estimated at $5.92 million under it, the former controlled 2.77% of total outstanding shares. On the other hand, Fidelity Securities Fund-Fidelity Small Cap Growth Fund held about 2.40% of the shares, roughly 1.35 shares worth around $5.13 million.
